Dr. Garon on Differences Between Antiangiogenic Agents in Lung Cancer

Edward B. Garon, MD
Published: Friday, Sep 08, 2017



Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the differences between antiangiogenic agents in lung cancer.

Unlike bevacizumab (Avastin), ramucirumab (Cyramza) and nintedanib (Ofev) target the VEGF receptor. Ramucirumab is a monoclonal antibody and nintedanib is a tyrosine kinase inhibitor.

There have been multiple attempts to add a TKI to chemotherapy in order to achieve the same benefits seen with bevacizumab plus chemotherapy, says Garon.
 


Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the differences between antiangiogenic agents in lung cancer.

Unlike bevacizumab (Avastin), ramucirumab (Cyramza) and nintedanib (Ofev) target the VEGF receptor. Ramucirumab is a monoclonal antibody and nintedanib is a tyrosine kinase inhibitor.

There have been multiple attempts to add a TKI to chemotherapy in order to achieve the same benefits seen with bevacizumab plus chemotherapy, says Garon.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x